Risk factor
Poor trading liquidity
Profitability factor
Very strong margins and returns
About
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.
Target Price
The average target price of CONCORDBIO.BO is 1941 and suggests 64% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation
Buy
Sell